Using of SGLt2 Inhibitors in Patients With Type 2 DM
NCT06268977 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2024-02-21
Summary
To detect the efficacy of SGLT2i in improving the metabolic parameters in patients with type 2 diabetes.
\- To detect the side-effects of SGLT2i
Conditions
Interventions
- DRUG
-
SGLT2 inhibitor
a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-01
- Primary Completion
- 2025-03-01
- Completion
- 2025-03-30
More Related Trials
-
Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.
NCT07019012 ·Status: RECRUITING ·Phase: PHASE4
-
The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
NCT03458715 ·Status: UNKNOWN ·Phase: PHASE4
-
Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin
NCT01422590 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Sitagliptin Added to Insulin Therapy for Type 2 Diabetes
NCT01855087 ·Status: COMPLETED
-
Effect of Empagliflozin on Body Composition and Ketones
NCT03877406 ·Status: UNKNOWN ·Phase: PHASE4
-
Sitagliptin in Combination With Metformin and Sulfonylurea
NCT00686634 ·Status: COMPLETED ·Phase: PHASE4
-
Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)
NCT00704132 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
NCT02202161 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
NCT00758069 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin
NCT01341717 ·Status: COMPLETED ·Phase: PHASE4
-
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)
NCT00094770 ·Status: COMPLETED ·Phase: PHASE3
-
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
NCT02556918 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
NCT01449747 ·Status: COMPLETED ·Phase: PHASE4
-
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
NCT01590797 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Effect of Sitagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes
NCT02900417 ·Status: UNKNOWN ·Phase: NA
-
Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2
NCT02719756 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress
NCT00699322 ·Status: UNKNOWN ·Phase: PHASE4
-
Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy
NCT02338921 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy
NCT03700801 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus
NCT01545024 ·Status: UNKNOWN
-
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
NCT01937598 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)
NCT00830076 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus
NCT00551590 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
NCT00127192 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus
NCT01642108 ·Status: UNKNOWN ·Phase: NA